- Revive Therapeutics (OTCQB:RVVTF) is exploring the use of the drug Bucillamine as a potential novel treatment for infectious diseases, including influenza and COVID-19.
- The company has applied for a provisional patent with the USPTO, entitled “Use of Bucillamine in the Treatment of Infectious Diseases”.
- Bucillamine is a disease-modifying anti-rheumatic drug marketed in Japan and South Korea for the treatment of rheumatoid arthritis.
Revive Therapeutics to explore bucillamine for COVID-19
Recommended For You
More Trending News
About RVVTF Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
RVVTF | - | - |
Revive Therapeutics Ltd. |